EUVIMEDEUVIMED entdecken
Crossref

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

Zobair M Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M Al-Naamani, Frank Tacke, Emmanouil Tsochatzis, Javier Crespo, Mohamed El-Kassas, Fernando Bril, Marco Arrese, Cyrielle Caussy, C Wendy Spearman und 38 weitere

Clinical Gastroenterology and Hepatology · 2026-09 · 24 (9) · 2333-2347

DOI: 10.1016/j.cgh.2026.03.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Zobair M Younossi und 49 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH/MASH Council, Washington, District of Columbia; Global Center for Liver Outcomes and Policy Research, Georgetown University School of…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Siemens Healthineers USA, Madrigal Pharmaceuticals Inc, Siemens Healthineers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have increased in prevalence alongside the global epidemics of obesity and type 2 diabetes and now represent one of the leading causes of chronic liver disease. Patients with MASLD and significant fibrosis (≥F2) are at increased risk for adverse outcomes. With advances in noninvasive tests (NITs) and the recent approval of resmetirom and semaglutide for noncirrhotic MASH with F2-F3 fibrosis, we provide updated consensus guidance on standardized risk stratification, treatment initiation, and response monitoring. METHODS: A structured Delphi process was conducted following a systematic updated literature review (January 2025-November 2025), covering the period since publication of the initial consensus recommendations, and included iterative anonymous voting among 40 international experts representing hepatology, gastroenterology, endocrinology, internal medicine, and primary care. Consensus was predefined as ≥70% agreement. RESULTS: Forty-two statements were developed; 86% achieved consensus in the first round, and all remaining statements reached consensus after refinement and the second round. The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification. Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient's cardiometabolic profile. Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF. CONCLUSIONS: This updated international consensus provides practical algorithms that integrate most commonly used noninvasive testing with recently approved pharmacologic therapies for MASLD, addressing current variability in clinical practice and supporting standardized implementation of risk-based care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseFatty LiverMetabolic DiseasesHumansRisk AssessmentDelphi TechniqueSemaglutideLiver Cirrhosis

Stichwörter der Autor:innen

Global ConsensusMASLDRisk Stratification

Substanzen

Semaglutide

Autor:innen und Institutionen

  • The Global NASH/MASH Council, Washington, District of Columbia; Global Center for Liver Outcomes and Policy Research, Georgetown University School of Medicine, Washington, District of Columbia. Electronic address: zobai…
  • The Global NASH/MASH Council, Washington, District of Columbia; Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • The Global NASH/MASH Council, Washington, District of Columbia; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, People's R…
  • The Global NASH/MASH Council, Washington, District of Columbia; Division of Gastroenterology and Hepatology, Department of Medicine, The Medical City for Military and Security Services, Muscat, Oman.
  • The Global NASH/MASH Council, Washington, District of Columbia; Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin,…
  • The Global NASH/MASH Council, Washington, District of Columbia; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.

Förderung

  • Siemens Healthineers USA
  • Madrigal Pharmaceuticals Inc
  • Siemens Healthineers

Zitieren

APA

Younossi, Z. M., Kalligeros, M., Wong, V. W., Al-Naamani, K. M., Tacke, F., Tsochatzis, E., Crespo, J., El-Kassas, M., Bril, F., Arrese, M., Caussy, C., Spearman, C. W., Gastaldelli, A., Pessoa, M. G., Gadano, A., Shubrook, J. H., Duseja, A., Eguchi, Y., Chan, W. K., …, & Henry, L. (2026). Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology, 24(9), 2333-2347. https://doi.org/10.1016/j.cgh.2026.03.030

Vancouver

Younossi ZM, Kalligeros M, Wong VW, Al-Naamani KM, Tacke F, Tsochatzis E, et al. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026;24(9):2333-2347. doi:10.1016/j.cgh.2026.03.030

BibTeX
@article{Younossi2026,
  author = {Younossi, Zobair M and Kalligeros, Markos and Wong, Vincent Wai-Sun and Al-Naamani, Khalid M and Tacke, Frank and Tsochatzis, Emmanouil and Crespo, Javier and El-Kassas, Mohamed and Bril, Fernando and Arrese, Marco and Caussy, Cyrielle and Spearman, C Wendy and Gastaldelli, Amalia and Pessoa, Mário Guimarães and Gadano, Adrian and Shubrook, Jay H and Duseja, Ajay and Eguchi, Yuichiro and Chan, Wah-Kheong and Fan, Jian-Gao and Holleboom, Adriaan G and Yu, Ming-Lung and Kim, James and Kawaguchi, Takumi and Villela-Nogueira, Cristiane and Oliveria, Claudia P and Kong, Alice Pik-Shan and Lam, Brian and Giles, Hochong and Betel, Michael and Ong, Janus P and Burra, Patrizia and Yilmaz, Yusef and Pearlman, Brian and Buti, Maria and Papatheodoridis, George and Abreu, Eliabe S and Abdelmalek, Manal and Alkhouri, Naim and Nader, Fatema and Stepanova, Maria and Racila, Andrei and Paik, James and Ivancovsky Wajcman, Dana and Grinshpan, Laura Sol and Roberts, Stuart K and Alqahtani, Saleh A and Zelber-Sagi, Shira and Castera, Laurent and Henry, Linda},
  title = {Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {9},
  pages = {2333--2347},
  doi = {10.1016/j.cgh.2026.03.030}
}
Kostenlos starten →